Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780

摘要: PURPOSE: To investigate the combination of docetaxel, estramustine (EM), and low-dose hydrocortisone in men with hormone-refractory prostate cancer (HRPC). PATIENTS AND METHODS: Combinations EM other antimitotic agents such as docetaxel are synergistic vitro show significant clinical activity patients HRPC. We studied intravenous administration 70 mg/m2, oral estramustine, daily HRPC who demonstrated progression after initial hormone therapy. RESULTS: Of 47 enrolled onto this multicenter cooperative group study, 46 were assessable for response and/or toxicity. In 24 measurable disease, there three complete nine partial responses a disease rate 50% (12 patients; 95% confidence interval [CI], 27% to 73%). 44 whom pretreatment prostate-specific antigen (PSA) was elevated, 30 (68%) had or greater decrease, 25 (57%) 75% dec...